—
TMC Life Sciences Berhad (TMCLS), a leading player in the healthcare industry, is poised for significant growth in the financial year ending 30 June 2024 (FY24), focusing on enhancing services for women and children.
[L-R] Dr. Siva Kumaran Jayaraman, Acting Chief Executive Officer of Thomson Hospital Kota Damansara, Dr. Heng Jun Li Melvin, Acting Group Chief Executive Officer of TMC Life Sciences Berhad, Datuk Seri Mohd Mokhtar bin Haji Mohd Shariff, Chairman of TMC Life Sciences Berhad, Kan Kheong Ng, Executive Vice Chairman of TMC Life Sciences Berhad, Lakshmi Menon, Chief Executive Officer of TMC Fertility and Jimmy Wong Yu Chee, Group Chief Financial Officer of TMC Life Sciences Berhad.
During the group’s 22nd Annual General Meeting (AGM) today, Chairman YBhg. Dato’ Sri Mohd Mokhtar bin Mohd Shariff highlighted the Group's strong financial position, reporting RM188.6 million in cash and bank balances for FY2024, a 13% year-on-year increase. This reflects the Group’s strong financial stability and commitment to the highest standards of corporate governance and risk management practices.
“The FY2024 results underscore our robust foundation and resilience in navigating market challenges. We are dedicated to sustaining profitability through meticulous expense management and strategic growth initiatives,” stated Dato’ Sri Mohd Mokhtar.
Profit before tax increased by 29% to RM52.6 million year-on-year for FY2024. In line with this positive performance and in conjunction with Celebrating Life for 30 years, the Board has recommended a final single-tier dividend of 0.4898 sen per ordinary share, alongside a special single-tier dividend of 1.7271 sen per ordinary share for FY2024.
Acting Group CEO, Dr Melvin Heng Jun Li, expressed strong optimism for FY2025, saying, “As we embark on this new fiscal year, we do so with a renewed commitment and a clear vision for excellence. Our strategies perfectly aligned with our growth objectives and our aim of delivering enhanced patient care.”
Key highlights from FY2024 include the successful partnership between Thomson Hospital Kota Damansara (Thomson) and OncoCare Medical Malaysia Sdn. Bhd. This collaboration, established on 5 September 2024, enhances the Thomson’s oncology offerings, showcasing TMCLS’s dedication to advancing cancer care.
Notably, Thomson made history in July 2023 by becoming the first hospital in Southeast Asia to administer the US-approved Spinraza for Spinal Muscular Atrophy. Additionally, the hospital also performed its first bowel atresia surgery on a premature infant in April 2024, demonstrating a commitment to pioneering medical procedures.
TMCLS is also committed to addressing climate change, with initiatives designed to achieve Net Zero by 2050. The Group's dedication to sustainable practices aligns seamlessly with its ongoing efforts to expand its footprint in the healthcare sector while prioritising Environmental, Social, and Governance (ESG) principles.
Looking ahead, TMC Life Sciences is strategically poised to capitalise on growth opportunities in the region, driven by increased capacity at Thomson and a resurgence in the fertility business through TMC Fertility. Additionally, a promising uptick in medical tourism further enhances the Group's potential for success.
Contact Info:
Name: Shobena Singam
Email: Send Email
Organization: TMC Life Sciences Berhad
Website: https://www.tmclife.com/
Release ID: 89145637
Google
RSS